Skip to main content
. 2017 Jul 4;8(45):78379–78396. doi: 10.18632/oncotarget.18987

Table 5. Primary and secondary antibodies used in this study.

Antibody MW (kDa) Dilution Sources
mTOR 289 1:1000 Cell Signalling
PI3K-ClassIII 100 1:1000 Cell Signalling
AMPKa 62 1:1000 Cell Signalling
P62 62 1:1000 Cell Signalling
AKT 60 1:1000 Cell Signalling
Beclin-1 60 1:1000 Cell Signalling
Cyclin D 34 1:1000 Cell Signalling
LC3-I 16 1:1000 Cell Signalling
LC3-II 14 1:1000 Cell Signalling
GADPH 36 1:10000 Cell Signalling
anti-Rabbit (IgG) 1:5000 GeneTex
anti-Mouse (IgG) 1:10000 GE